Equities

LungLife AI Inc

LungLife AI Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)17.50
  • Today's Change0.00 / 0.00%
  • Shares traded13.64k
  • 1 Year change-57.83%
  • Beta--
Data delayed at least 20 minutes, as of Jun 06 2024 10:25 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

LungLife AI, Inc. is a developer of clinical diagnostic solutions for lung cancer. The Company is engaged in the development and commercialization of its lung cancer early detection test. Using a minimally invasive blood draw, its LungLB test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. LungLB is a blood-based liquid biopsy assay that uses fluorescence in situ hybridization (FISH) and image analysis to identify circulating genetically abnormal cells (CGAC), which include circulating tumor cells (CTCs). The technique incorporates an artificial intelligence (AI)-derived image analysis strategy to identify unique cell populations reflective of the disease state under interrogation.

  • Revenue in GBP (TTM)36.04k
  • Net income in GBP-4.24m
  • Incorporated2009
  • Employees15.00
  • Location
    LungLife AI Inc2545 W. Hillcrest Drive, Suite 140THOUSAND OAKS 91320United StatesUSA
  • Phone+1 (805) 409-9868
  • Fax+1 (805) 855-2003
  • Websitehttps://lunglifeai.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cambridge Nutritional Sciences PLC9.05m-3.21m10.11m91.00--1.09--1.12-0.0136-0.01050.03850.03910.58573.972.0599,406.59-20.81-10.49-23.88-11.9052.9059.24-35.53-27.404.22-128.470.0225---11.63-1.96-125.12---45.83--
Kanabo Group PLC895.00k-7.99m10.75m20.00--1.43--12.01-0.0137-0.01370.00170.01190.078511.1128.41---70.12-75.83-77.61-83.3314.97---893.30-1,267.354.96-10.430.035--48.42---16.26------
ImmuPharma PLC69.96k-2.99m10.87m13.00--5.01--155.36-0.0092-0.00920.00020.00520.0227--0.17065,381.54-97.05-89.69-159.35-106.57-----4,275.31-7,958.69---2.400.00---100.00--53.42--32.98--
Chill Brands Group PLC146.62k-3.64m10.89m2.00------74.24-0.0142-0.01420.0006-0.00240.03190.09920.363973,310.00-79.21-72.55-141.46-105.3553.05---2,485.30-1,625.460.6499-8.481.17---86.73-50.8923.50---35.95--
Genflow Biosciences PLC0.00-1.63m11.54m5.00--13.30-----0.0056-0.00560.000.00250.00----0.00-88.30---105.34--------------0.00-------21.97------
Proteome Sciences plc5.03m-2.44m11.81m35.00------2.35-0.0083-0.00830.017-0.01040.42093.893.04143,657.10-20.45-1.22----32.7654.53-48.59-2.200.2667-2.031.29---35.3710.52-284.38--126.22--
Oncimmune Holdings PLC1.21m-3.19m13.23m56.00------10.90-0.04270.09390.0163-0.01720.17561.190.6917---46.21------63.34---263.10--1.01-0.68151.32--------------
Synairgen plc0.00-9.99m13.57m30.00--0.8502-----0.0496-0.04960.000.07930.00----0.00-41.40-54.75-48.86-60.72-------83,247.62----0.00------63.74--0.00--
Provexis plc598.08k-496.59k13.58m2.00--13.54--22.70-0.0002-0.00020.00030.00040.67173.042.95299,040.00-55.78-48.82-41.86-33.6846.7286.14-83.03-97.641.96--0.00---8.5110.58-71.79------
Genincode PLC1.72m-6.73m13.71m28.00--1.56--7.99-0.0703-0.07030.01790.04970.16816.362.8861,285.71-65.92---72.37--47.55---392.31--5.85--0.0632--23.92---34.21------
Abingdon Health PLC5.34m-2.24m14.19m82.00--7.52--2.66-0.0184-0.01840.04390.01490.89787.674.7465,170.73-37.55-51.31-58.04-79.8557.3533.16-41.82-139.641.59--0.3572--42.68--83.77------
LungLife AI Inc36.04k-4.24m14.76m15.00--0.7423--409.62-0.1664-0.16640.00140.24330.0038--0.28312,402.76-44.11---50.09--100.00---11,767.39------0.0419--91.67--28.83------
Shield Therapeutics PLC13.09m-33.29m14.86m73.00--0.9884--1.14-0.0458-0.04580.01810.01920.3473.651.31179,246.60-88.29-56.68-136.30-67.4430.7852.20-254.44-365.892.04-30.010.5739--137.951.9533.13---2.50--
Destiny Pharma PLC0.00-5.66m15.04m19.00--1.63-----0.0624-0.06240.000.09650.00----0.00-60.33-54.32-67.28-59.97------------0.00------13.02--35.39--
OptiBiotix Health PLC689.10k-13.17m17.14m3.00--1.70--24.87-0.1489-0.14890.00780.10290.04262.281.25229,700.00-81.3517.83-83.4318.6649.3154.87-1,911.88190.543.24-0.0890.00---79.3519.05-58.686.2830.03--
Verici DX PLC793.70k-6.84m18.86m14.00--4.75--23.76-0.0402-0.04020.00470.01640.0932--1.5956,692.55-80.32---115.94--1.58---862.19------0.0438------23.43------
Data as of Jun 06 2024. Currency figures normalised to LungLife AI Inc's reporting currency: UK Pound GBX

Institutional shareholders

11.84%Per cent of shares held by top holders
HolderShares% Held
Unicorn Asset Management Ltd.as of 30 Apr 20241.75m6.87%
Lombard Odier Asset Management (Europe) Ltd.as of 22 Mar 20241.27m4.98%
SVM Asset Management Ltd.as of 30 Jun 20230.000.00%
Data from 31 Mar 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.